| Fred Harrison Williams, MD | |
|
121 Saint Lukes Center Dr, Suite 406, Chesterfield, MO 63017-3509 | |
| (314) 432-5900 | |
| (314) 434-2679 |
| Full Name | Fred Harrison Williams |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 38 Years |
| Location | 121 Saint Lukes Center Dr, Chesterfield, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386644326 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 118411 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Lukes Hospital | Chesterfield, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gateway Gastroenterology Inc | 2668448713 | 10 |
News Archive
UNT Health Science Center will team up with JPS Health Network, Texas Christian University and the United Way's Area Agency on Aging of Tarrant County to transform geriatric care in North Texas by improving medical training and health-care delivery for the region's rapidly growing population of older residents.
Depressed individuals with a tendency to ruminate on negative thoughts, i.e. to repeatedly think about particular negative thoughts or memories, show different patterns of brain network activation compared to healthy individuals, report scientists of a new study in Biological Psychiatry.
In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium.
Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.
Inhibitex, Inc., announced today that it has completed enrollment in a Phase II clinical trial of FV-100 in shingles (herpes zoster) patients. The objectives of the trial are to further evaluate the safety of FV-100 and its potential therapeutic benefit in reducing the severity and duration of shingles-associated pain, the incidence of post herpetic neuralgia (PHN), and the time to heal shingles-related lesions.
› Verified 9 days ago
| Entity Name | Gateway Gastroenterology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043250400 PECOS PAC ID: 2668448713 Enrollment ID: O20040909000422 |
News Archive
UNT Health Science Center will team up with JPS Health Network, Texas Christian University and the United Way's Area Agency on Aging of Tarrant County to transform geriatric care in North Texas by improving medical training and health-care delivery for the region's rapidly growing population of older residents.
Depressed individuals with a tendency to ruminate on negative thoughts, i.e. to repeatedly think about particular negative thoughts or memories, show different patterns of brain network activation compared to healthy individuals, report scientists of a new study in Biological Psychiatry.
In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium.
Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.
Inhibitex, Inc., announced today that it has completed enrollment in a Phase II clinical trial of FV-100 in shingles (herpes zoster) patients. The objectives of the trial are to further evaluate the safety of FV-100 and its potential therapeutic benefit in reducing the severity and duration of shingles-associated pain, the incidence of post herpetic neuralgia (PHN), and the time to heal shingles-related lesions.
› Verified 9 days ago
| Entity Name | Urgent Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255820510 PECOS PAC ID: 4486995800 Enrollment ID: O20190412001473 |
News Archive
UNT Health Science Center will team up with JPS Health Network, Texas Christian University and the United Way's Area Agency on Aging of Tarrant County to transform geriatric care in North Texas by improving medical training and health-care delivery for the region's rapidly growing population of older residents.
Depressed individuals with a tendency to ruminate on negative thoughts, i.e. to repeatedly think about particular negative thoughts or memories, show different patterns of brain network activation compared to healthy individuals, report scientists of a new study in Biological Psychiatry.
In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium.
Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.
Inhibitex, Inc., announced today that it has completed enrollment in a Phase II clinical trial of FV-100 in shingles (herpes zoster) patients. The objectives of the trial are to further evaluate the safety of FV-100 and its potential therapeutic benefit in reducing the severity and duration of shingles-associated pain, the incidence of post herpetic neuralgia (PHN), and the time to heal shingles-related lesions.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fred Harrison Williams, MD 121 Saint Lukes Center Dr, Suite 406, Chesterfield, MO 63017-3518 Ph: (314) 529-4900 | Fred Harrison Williams, MD 121 Saint Lukes Center Dr, Suite 406, Chesterfield, MO 63017-3509 Ph: (314) 432-5900 |
News Archive
UNT Health Science Center will team up with JPS Health Network, Texas Christian University and the United Way's Area Agency on Aging of Tarrant County to transform geriatric care in North Texas by improving medical training and health-care delivery for the region's rapidly growing population of older residents.
Depressed individuals with a tendency to ruminate on negative thoughts, i.e. to repeatedly think about particular negative thoughts or memories, show different patterns of brain network activation compared to healthy individuals, report scientists of a new study in Biological Psychiatry.
In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium.
Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.
Inhibitex, Inc., announced today that it has completed enrollment in a Phase II clinical trial of FV-100 in shingles (herpes zoster) patients. The objectives of the trial are to further evaluate the safety of FV-100 and its potential therapeutic benefit in reducing the severity and duration of shingles-associated pain, the incidence of post herpetic neuralgia (PHN), and the time to heal shingles-related lesions.
› Verified 9 days ago
Lovepreet Singh Randhawa, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 224 S Woods Mill Rd, Chesterfield, MO 63017 Phone: 314-205-6050 Fax: 314-205-6350 | |
Rachel Lynn Fishman Oiknine, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 222 S Woods Mill Rd, Suite 410n, Chesterfield, MO 63017 Phone: 314-469-6224 Fax: 314-469-0744 | |
Xiaoling Wu, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 224 S Woods Mill Rd, Suite 370 South, Chesterfield, MO 63017 Phone: 314-878-2460 | |
Daniel B Bauwens, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 232 S Woods Mill Rd, Chesterfield, MO 63017 Phone: 314-576-5023 | |
Michael Carl Fusco, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 14528 S Outer 40, Suite 300, Chesterfield, MO 63017 Phone: 314-214-8100 Fax: 314-214-8233 | |
David H Cort, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 226 S Woods Mill Rd, Suite 52 West, Chesterfield, MO 63017 Phone: 314-434-2399 Fax: 314-434-5653 | |
Meghashyam Jayateerth Koti, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 15740 S Outer 40 Rd # C, Chesterfield, MO 63017 Phone: 636-735-4963 |